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Objectives.EvaluationofpharmacokineticsandpharmacodynamicsofdarunavirandetravirineamongHIV-1–infected,treatment-
experienced adults from GRACE, by sex and race. Methods. Patients received darunavir/ritonavir 600/100mg twice daily plus other
antiretrovirals, which could include etravirine 200mg twice daily. Population pharmacokinetics for darunavir and etravirine were
determined over 48 weeks and relationships assessed with virologic response and safety. Rich sampling for darunavir, etravirine,
and ritonavir was collected in a substudy at weeks 4, 24, and 48. Results. Pharmacokinetics were estimated in 376 patients for
darunavir and 190 patients for etravirine. Median darunavir AUC12h and C0h were 60,642ng·h/mL and 3624ng/mL, respectively;
and for etravirine were 4183ng·h/mL and 280ng/mL, respectively. There were no diﬀerences in darunavir or etravirine AUC12h or
C0h by sex or race. Age, body weight, or use of etravirine did not aﬀect darunavir exposure. No relationships were seen between
darunavir pharmacokinetics and eﬃcacy or safety. Patients with etravirine exposure in the lowest quartile generally had lower
response rates. Rich sampling showed no time-dependent relationship for darunavir, etravirine, or ritonavir exposure over 48
weeks. Conclusions. Population pharmacokinetics showed no relevant diﬀerences in darunavir or etravirine exposure by assessed
covariates. Lower etravirine exposures were associated with lower response rates.
1.Introduction
Diﬀerencesinantiretroviralpharmacokineticparametersbe-
tween women and men, caused by variables such as body
weight, plasma volume, and cytochrome P450 activity, could
lead to diﬀerent drug concentrations and toxicity proﬁles be-
tween sexes [1–3]. Previous pharmacokinetic data from the
antiretroviral therapy with TMC114 examined in na¨ ıve sub-
jects (ARTEMIS) and TMC114/r in treatment-experienced
patients na¨ ıve to lopinavir (TITAN) trials, which studied 343
treatment-na¨ ıve and 298 treatment-experienced patients re-
ceiving darunavir/ritonavir, respectively, have demonstrated
small, nonclinically relevant diﬀerences in darunavir phar-
macokineticparametersbetweenwomenandmenandacross
races [4, 5]. The once-daily darunavir in treatment-experi-
enced patients (ODIN) trial, which studied 294 patients re-
ceiving once-daily darunavir versus 296 patients receiving
twice-daily darunavir, found that women had higher expo-
sures than men, and Asian patients had lower exposure than
white patients; however, these diﬀerences were not consid-
ered clinically signiﬁcant [6]. Data from the pooled TMC125
to demonstrate undetectable viral load in patients experie-
nced with antiretroviral therapy (DUET)-1 and DUET-2 tri-
als, which compared treatment with etravirine (n = 599)2 AIDS Research and Treatment
versus placebo (n = 604) in treatment-experienced patients,
didnotdemonstrateanysexorracialdiﬀerencesinetravirine
pharmacokinetic parameters [7]. These trials, however, were
not speciﬁcally designed to investigate sex-based or race-
based diﬀerences in darunavir or etravirine pharmacokinet-
ics.
The gender, race, and clinical experience (GRACE) study
was speciﬁcally designed to assess sex-based and race-based
diﬀerences in the pharmacokinetics, eﬃcacy, and safety of
darunavir/ritonavir-basedtherapyintreatment-experienced,
HIV-1–infected patients by enrolling a high proportion of
women and people of color [8]. This paper presents the dar-
unavir, ritonavir, and etravirine pharmacokinetic data from
GRACE by sex and race, and the relationship of darun-
avir and etravirine pharmacokinetics with eﬃcacy and sa-
fety, collected over 48 weeks. The relationship between ex-
trinsic and intrinsic covariates with darunavir pharmacoki-
netics is also investigated.
2.MaterialsandMethods
2.1. Study Design and Treatment. GRACE was a 48-week,
open-label, Phase IIIb study conducted at 65 study sites
across the United States, Canada, and Puerto Rico. Treat-
ment-experienced adults with HIV-1 RNA ≥1000 copies/mL
received darunavir 600mg coadministered with ritonavir
100mg twice daily with other antiretrovirals, which could
include etravirine 200mg twice daily. The choice of addi-
tional antiretrovirals was based on resistance testing (vir-
coTY-PE HIV-1). During enrollment, the vircoTYPE
HIV-1 resistance test used did not include etravirine, which
resulted in some patients with reduced susceptibility to etra-
virine receiving the drug. Subsequently, at the time of data
analysis, baseline samples were reanalyzed using an updated
version of the vircoTYPE HIV-1 resistance test interpreta-
tion, which included etravirine. The data referenced in this
paper are those obtained from the updated analysis. Women
who were pregnant were excluded from the study. Other in-
clusion/exclusion criteria and study visits have been de-
scribed previously [8]. Human experimentation guidelines
of the United States Department of Health and Human
Services and the Declaration of Helsinki were followed in
the conduct of this clinical research; the research protocol
was reviewed and approved by institutional review boards
for all 65 study sites; written informed consent was provided
by all participants prior to study initiation. Details of
the study design were registered at clinicaltrials.gov (ID:
NCT00381303).
2.2. Pharmacokinetic Analysis. Sparse sampling for the de-
termination of darunavir and etravirine (if applicable) phar-
macokinetic parameters was performed at Weeks 4, 8, 24,
and 48. Two samples were taken at Weeks 4 and 24, one im-
mediately before intake of medication and one at least an
hour after intake of medication. At Weeks 8 and 48, the
samples could be taken at any time after intake of medica-
tion.Pharmacokineticswereconsideredevaluableifthesam-
ple had measurable darunavir and ritonavir or etravirine
(if applicable) concentrations, and if the time of last intake
or administration was known. Previously developed popu-
lation pharmacokinetic models [7, 9] were applied to the
sparse sampling data to derive empirical Bayesian estimates
ofdarunavirandetravirineareaundertheplasmaconcentra-
tion–time curve (AUC12h) and trough concentration (C0h).
In a subset of consenting patients from the pharmacoki-
netic substudy, intensive blood sampling for darunavir, rito-
navir, and etravirine (if applicable) was conducted over 12
hours; samples were collected before dose and 1, 2, 3, 4, 6, 9,
and12hoursafterdoseatWeeks4,24,and48.Ritonavircon-
centrations were determined to assess adherence to that me-
dication. Patients were required to have fasted for 10 hours
before arrival at the testing site. A standardized breakfast
was served at the facility, and medications were administered
within 30 minutes of the meal. In order to be included in the
intensive pharmacokinetic sampling, patients had to volun-
teer and already participate at a study site that was involved
in the intensive pharmacokinetic analysis.
Plasma concentrations of darunavir, ritonavir, and etra-
virineinthemainstudyandsubstudyweredeterminedusing
a previously validated liquid chromatography–tandem mass
spectrometry method; the lower limit of quantiﬁcation was
10.0ng/mL, 5.0ng/mL, and 2.0ng/mL for darunavir, riton-
avir, and etravirine, respectively [10].
Relationships between darunavir and etravirine pharma-
cokinetics (Bayesian estimated AUC12h and C0h)a n dv i r o -
logic eﬃcacy at Week 48, measured by change in log10 viral
load (VL) from baseline and the proportion of patients
achieving a VL less than 50 copies/mL, were assessed using
analysis of covariance models. The impact of extrinsic and
intrinsic covariates (use of etravirine [relationship with dar-
unavir pharmacokinetics only] and use of tenofovir diso-
proxilfumarate[TDF],age,sex,race,bodyweight,andhepa-
titis B coinfection status) on darunavir and etravirine phar-
macokinetics was explored graphically, using descriptive
statistics and by analysis of covariance. Tenofovir disoproxil
fumarate was included in the covariate analysis due to pre-
vious evaluations suggesting a drug-drug interaction with
etravirine [11]. Relationships between darunavir and etra-
virine pharmacokinetics and safety (rash-, cardiac-, ga-
strointestinal-, liver-, lipid-, glucose-, psychiatric-, and ner-
voussystem–associatedadverseevents),includinglaboratory
assessments, were investigated and are presented using de-
scriptive statistics. Week 48 pharmacokinetic data were used
to evaluate all relationships with eﬃcacy, covariates, and
safety.
3. Results
3.1. Patient Populations and Baseline Characteristics. GRACE
enrolled a total of 429 patients, of whom 66.9% were wom-
en, 61.5% were black, 22.4% were Hispanic, and 15.2% were
white. In the intent–to–treat time–to–loss of virologic re-
sponse analysis of the overall population, 53.4% of patients
achieved virologic response (HIV-RNA <50 copies/mL) after
48 weeks; women had a lower response compared with men
(50.9% [conﬁdence interval (CI) range: 45.1%–56.7%] andAIDS Research and Treatment 3
58.5% [50.3%–66.6%], resp.), and black patients had a low-
er response rate compared with Hispanic and white pa-
tients (48.5% [42.5%–54.5%], 61.5% [51.7%–71.2%], and
60.0% [48.1%–71.9%], resp.) [8, 12]. Patients who received
etravirine had slightly higher response rates than did the
overall population. In the intent–to–treat time–to–loss of
virologic response analysis of the etravirine population,
59.4% of patients achieved virologic response; women had
a slightly lower response rate compared with men (58.0%
[49.1%–66.9%]and61.4%[51.2%–71.5%],resp.),andblack
patients had a lower response rate compared with Hispanic
or white patients (55.6% [47.2%–64.1%], 69.4% [54.4%–
84.5%], and 61.8% [45.4%–78.1%], resp.) [12, 13].
Of the 429 patients in the overall GRACE population,
evaluable pharmacokinetic data from sparse sampling were
available for 376 patients (Table 1). Among these patients,
66%(n = 248)werewomen,60%(n = 226)wereblack,22%
(n = 84) were Hispanic, 17% (n = 62) were white, and 1%
(n = 4) were Asian or other. In total, 37 patients—including
25 women, 12 men, 25 black patients, 10 Hispanic patients,
and 2 white patients—underwent intensive pharmacokinetic
sampling.
Of the 207 patients who received etravirine in addition to
darunavir (Table 1), evaluable pharmacokinetic data from
sparse sampling were available for 190 patients. These pa-
tients included 108 (57%) women, 122 (64%) black, 33
(17%) Hispanic, 31 (16%) white, and 4 (2%) Asian or other
patients. Of the patients who received etravirine, 16 under-
went intensive pharmacokinetic sampling, including 8 wom-
en, 11 black, 4 Hispanic, and 1 white patient.
3.2. Pharmacokinetics
3.2.1. Population Pharmacokinetic Analyses over 48 Weeks.
Among the 429 patients enrolled in this trial, 222 did not
receive etravirine and 207 received at least one dose of etra-
virine. Based on pharmacokinetic data available for 376 pa-
tients, including both recipients and nonrecipients of etra-
virine, the median (range) darunavir AUC12h and C0h were
60,642 (26,117–128,790) ng·h/mL and 3624 (931–9570)
ng/mL,respectively.Basedonpharmacokineticdataavailable
for 187 patients who did not receive etravirine, the median
(range) darunavir AUC12h and C0h were 58,933 (26,117–
128,790) ng·h/mL and 3489 (1036–9570) ng/mL, respec-
tively. Based on pharmacokinetic data available for 189 pa-
tients who received etravirine, the median (range) darunavir
AUC12h and C0h were 62,626 (30,960–109,410) ng·h/mL and
3806 (931–7473) ng/mL, respectively. In those patients who
received etravirine, the median (range) etravirine AUC12h
and C0h were 4183 (212–27,960) ng·h/mL and 280 (4–2211)
ng/mL, respectively. Analysis of darunavir and etravirine
pharmacokinetics by sex and race showed no clinically
relevant diﬀerence in AUC12h or C0h between sexes or across
races. Based on univariate analysis, hepatitis B co-infection
status, age, body weight, or use of etravirine or TDF did not
aﬀect darunavir AUC12h or C0h (Table 2).
Patients with TDF in their background regimen had low-
er median etravirine exposure (AUC12h, 3998ng·h/mL; C0h,
258ng/mL) compared with those without TDF (AUC12h,
Table 1: Baseline demographics and disease characteristics for the
pharmacokinetic population (overall and etravirine populations).
Parameter Overall
N = 376
Etravirine
subgroup
n = 190
Sex, n (%)
Male 128 (34.0) 82 (43.2)
Female 248 (66.0) 108 (56.8)
Race, n (%)
Black 226 (60.1) 122 (64.2)
Hispanic 84 (22.3) 33 (17.4)
White 62 (16.5) 31 (16.3)
Asian/other 4 (1.1) 4 (2.1)
Median (range) age, years 43.0 (19.0, 78.0) 45.0 (19.0, 78.0)
Mean (SE) weight, kg 76.7 (1.03) 76.8 (1.50)
Mean (SE) BMI, kg/m2 27.3( 0 .35)
a 27.0 (0.50)
Mean (SE) duration of
HIV infection, years 11.3( 0 .29)
a 12.5 (0.38)
b
Mean (SE) HIV-1 RNA,
log10 copies/mL 4.64 (0.044) 4.60 (0.067)
Median (range) CD4+
count, cells/mm3 203 (2, 1125) 186 (1, 1125)
CDC Class C, n (%) 148 (39.4) 87 (45.8)
Median (range)
darunavir, fold changec 0.6( 0 .3, 607.9)
d 0.6 (0.3, 607.9)
Median (range)
etravirine, fold changec 1.3( 0 .3, 93.8)
d 1.4 (0.3, 93.8)
Prior use of ≥2P I s ,n (%) 228 (60.6) 135 (71.1)
an = 375. bn = 189. cvircoTYPE HIV-1 resistance analysis; patients
were considered susceptible to darunavir if the fold change was <3.4 and to
etravirine if the fold change was <3.2. dn = 374; 2 patients, one Hispanic
and one white (both women), did not have resistance testing at baseline.
SE: standard error; BMI: body mass index; CDC: United States Center for
Disease Control and Prevention; PI: protease inhibitor.
5051ng·h/mL; C0h, 329ng/mL), and patients with hep-
atitis B co-infection demonstrated a trend toward higher
median etravirine exposures (AUC12h, 5504ng·h/mL; C0h,
382ng/mL) compared with those without co-infection
(AUC12h, 4141ng·h/mL; C0h, 278ng/mL). We further ana-
lyzed several of these covariates using an analysis of covari-
ance (Table 3). Only age and female sex were statistically
correlatedwithhigherdarunavirexposure;olderagewasalso
correlated with higher etravirine exposure. However, none
of these associations were considered clinically relevant as
evidenced by univariate analysis.
3.2.2. Intensive Pharmacokinetic Analyses Over 48 Weeks. In-
tensive pharmacokinetic sampling showed no time-depend-
ent relationship for darunavir, ritonavir, or etravirine expo-
sure over 48 weeks; darunavir and etravirine intensive
pharmacokinetic results were generally similar to the popu-
lation pharmacokinetic results (Table 4). Mean plasma con-
centration–time proﬁles for darunavir were higher in wom-
en than in men, with an AUC12h approximately 18%, 33%,
and 14% higher in women than in men at Weeks 4, 24, and4 AIDS Research and Treatment
Table 2: Population pharmacokinetics at Week 48 (univariate analysis).
n
Darunavir
n
Etravirine
AUC12h
Median (range)
Ng·h/mL
C0h
Median (range)
ng/mL
AUC12h
Median (range)
ng·h/mL
C0h
Median (range)
ng/mL
Overall population 376 60,642 (26,117–128,790) 3624 (931–9570) 190 4183 (212–27,960) 280 (4–2211)
Age, years
≤30 39 58,309 (33,050–128,790) 3317 (1145–9570) 17 3476 (568–5261) 212 (5–331)
>30 to ≤50 260 59,955 (26,117–105,130) 3584 (931–6841) 128 4348 (212–27,960) 286 (4–2211)
>50 to ≤65 68 64,337 (40,299–120,880) 3957 (2215–8906) 38 4366 (295–11,684) 291 (11–890)
>65 9 63,978 (38,171–84,295) 3916 (1879–5869) 7 7484 (2213–17,921) 541 (126–1392)
Weight at baseline, kg
≤62.33 94 61,005 (32,271–128,790) 3665 (1169–9570) 46 3675 (295–17,921) 226 (11–1392)
>62.33 to ≤73.94 96 58,367 (29,888–93,408) 3489 (931–6081) 48 3824 (1004–20,495) 250 (42–1605)
>73.94 to ≤87.09 92 63,942 (34,692–105,130) 3903 (1568–6502) 52 4960 (212–27,960) 332 (4–2211)
>87.09 94 61,090 (26,117–100,710) 3561 (1258–6943) 44 4638 (1319–18,977) 314 (60–1487)
Hepatitis B co-infection
status
No 362 60,831 (26,117–128,790) 3618 (931–9570) 184 4141 (212–27,960) 278 (4–2211)
Yes 14 57,936 (37,506–97,125) 3718 (1640–6784) 6 5504 (3751–11,684) 382 (241–890)
Use of TDF
No 58 61,443 (38,104–109,410) 3489 (1169–7473) 45 5051 (295–17,921) 329 (11–1392)
Yes 318 60,601 (26,117–128,790) 3627 (931–9570) 145 3998 (212–27,960) 258 (4–2211)
Use of etravirine
No 187 58,933 (26,117–128,790) 3489 (1036–9570) NA NA NA
Yes 189 62,626 (30,960–109,410) 3806 (931–7473) NA NA NA
AUC12h: area under the plasma concentration–time curve over 12 hours; C0h: trough concentration; TDF: tenofovir disoproxil fumarate; NA: not applicable.
Table 3: Relationship of selected covariates with darunavir or etravirine pharmacokinetic parameters at Week 48—analysis of covariance.
Darunavir Etravirine
Covariate
Relationship
to AUC12h,
estimate (SE)
Relationship
to AUC12h,
adjusted
P value
Relationship
to C0h, estimate
(SE)
Relationship
to C0h,
adjusted P
value
Relationship
to AUC12h,
estimate (SE)
Relationship
to AUC12h,
adjusted P
value
Relationship
to C0h,
estimate (SE)
Relationship
to C0h,
adjusted P
value
Sex 0.028 (0.011) 0.011 0.050 (0.016) 0.002 −0.035 (0.049) 0.479 −0.049 (0.063) 0.432
Racea 0.246 0.115 0.808 0.843
Asian –0.099 (0.096) −0.136 (0.143) 0.369 (0.331) 0.452 (0.422)
Black –0.002 (0.068) 0.017 (0.101) 0.116 (0.236) 0.155 (0.301)
Hispanic 0.004 (0.069) 0.041 (0.103) 0.148 (0.242) 0.183 (0.308)
White 0.023 (0.069) 0.058 (0.103) 0.130 (0.240) 0.184 (0.306)
Other 0.000 0.000 0.000 0.000
Age,b years 0.001 (0.001) 0.005 0.003 (0.001) <0.001 0.005 (0.002) 0.029 0.007 (0.003) 0.023
Weight,b kg 0.000 (0.000) 0.839 0.000 (0.000) 0.784 0.002 (0.001) 0.179 0.002 (0.002) 0.149
Use of TDF –0.019 (0.014) 0.168 –0.038 (0.021) 0.072 NE NE NE NE
Use of
etravirine –0.024 (0.028) 0.389 –0.032 (0.042) 0.450 NA NA NA NA
aFive-waycomparison:white,black,Hispanic,Asian,andother. bModeledascontinuouslinearvariables. AUC12h:areaundertheplasmaconcentration–time
curve over 12 hours; SE: standard error; C0h: trough concentration; TDF: tenofovir disoproxil fumarate; NE: not evaluated; NA: not applicable.AIDS Research and Treatment 5
48, respectively. Ritonavir AUC12h was approximately 44%
higher in women at Weeks 4 and 24 and 8% lower in
women than in men at Week 48. Mean plasma concen-
tration–time proﬁles for both darunavir and ritonavir slight-
ly diﬀered when comparing black and Hispanic patients. For
darunavir, higher concentrations were observed for black
patients at Weeks 4 and 48 than for Hispanic patients. When
the intensive pharmacokinetic data for etravirine were brok-
en down by sex or race, the sample sizes were too small to
draw any deﬁnitive conclusions (Table 4).
3.2.3. Relationship between Pharmacokinetics (Sparse Sam-
pling) and Eﬃcacy. When the relationships between darun-
avir population pharmacokinetics and eﬃcacy parameters
were investigated, no relationships were observed between
darunavir AUC12h or C0h values and the change in log10 VL
from baseline to Week 48, or the proportion of patients
achieving less than 50 copies/mL by Week 48 in the overall
nonvirologic failure–censored population, which censored
patients who discontinued for reasons other than virologic
failure (Figure 1(a)). Furthermore, consistent with the above
results, no relationship between darunavir Week 48 pharma-
cokinetics and change in VL or virologic response was seen
by sex or race.
When the relationships between etravirine pharmacoki-
netics and eﬃcacy parameters in the nonvirologic failure–
censored population were investigated, patients with AUC12h
or C0h in the lowest quartile at Week 48 had the smallest
change in log10 VL from baseline to Week 48 (Figure 1(b)).
These patients in the lowest quartile of AUC12h or C0h at
Week 48 also demonstrated the lowest virologic response
rates, compared with the other pharmacokinetic quartiles
(Figure 1(b)).
3.2.4. Relationship between Pharmacokinetics and Safety.
When the relationships between darunavir and etravirine
pharmacokinetic parameters and safety in the overall popu-
lation were investigated, no apparent relationships were ob-
served between darunavir or etravirine AUC12h or C0h and
the incidence of rash-, cardiac-, gastrointestinal-, liver-, lip-
id-, glucose-, nervous system disorder–, or psychiatric dis-
order–associated adverse events (data not shown). Similarly,
no relationships were seen between darunavir pharmacoki-
netics and safety parameters by sex or race (data not shown).
4. Discussion
Sex and race did not appear to substantially aﬀect darunavir
or etravirine exposure. Similar darunavir exposures have
been observed in treatment-experienced patients from the
performance of TMC114/r when evaluated in treatment- ex-
perienced patients with PI resistance (POWER 1, 2, and 3
and TITAN trials [4, 14]). Likewise, previous studies of
etravirine pharmacokinetics have yielded median values
similar to those seen here [7]. Furthermore, the ranges of
darunavir and etravirine exposure observed in this study
were numerically similar to those from previous studies
[4, 7].
Although this study was not speciﬁcally powered to com-
pare the eﬀects of covariates on pharmacokinetics, all groups
(e.g., women versus men) were well represented, allowing for
meaningful comparisons. This study demonstrated that the
pharmacokinetic exposure (i.e., AUC12h and C0h)t od a r u n -
avir was not substantially inﬂuenced by sex, race, age, body
weight, hepatitis B co-infection status, or use of etravir-
ine or TDF, similar to results from other studies of darun-
avir/ritonavir in treatment-experienced, HIV-infected pa-
tients [4, 5, 7, 10, 15]. Trials of other HIV protease inhibitors
(PIs) have demonstrated an inﬂuence of various covariates
on pharmacokinetic parameters. For instance, 2 studies have
demonstrated signiﬁcant diﬀerences in exposure of saquin-
avirandindinavir betweenwomenandmen[16,17].Incon-
trasttothedarunavirpharmacokineticresults,patientsusing
TDForwithhepatitisBco-infectiondemonstratedtrendsto-
ward lower and higher etravirine exposure, respectively.
SimilarresultswereobtainedintheDUETtrialsandwerenot
deemed clinically relevant [7]. The eﬀect of TDF use was as
expected, based on a known drug-drug interaction [11], and
it should be noted that use of TDF did not aﬀect clinical out-
comes in this trial [8].
Although no clinically relevant sex-based diﬀerences in
population pharmacokinetic parameters were seen during
this trial, an analysis of covariance (which showed statistical
diﬀerencesandintensivepharmacokineticsamplinginasub-
set of patients), did suggest a trend toward higher darunavir
and ritonavir exposure in women compared with men.
Similar results were seen in TITAN, which suggested that
women had slightly higher darunavir exposures than men
(∼15% higher) and that black patients had slightly higher
darunavirexposuresthanwhitepatients(∼8%higher);these
diﬀerences were not considered clinically relevant. The trend
toward increased darunavir exposure in women, observed
in this trial and in TITAN, may be due to several factors,
including, but not limited to, physiologic diﬀerences in
protein binding, gastric motility, sex hormones, and/or α1-
acid glycoprotein (AAG) levels [18]. Elevated AAG levels
have been linked to increased PI binding and, therefore,
exposure [19, 20]. Indeed, at baseline, women in the phar-
macokinetic substudy of the GRACE trial had AAG levels
approximately 12% higher than those of men [21]. Recently,
a post hoc analysis of the GRACE pharmacokinetic Week
4 substudy investigated the relationship of plasma estrone
sulfate (E3S), a sex hormone, with darunavir and ritonavir
pharmacokinetics [22]. In this case, no diﬀerences were seen
in the plasma concentrations of E3S between women and
men in the substudy. Additionally, although E3S and dar-
unavir were both substrates for the hepatic uptake tran-
sporter SLCO1B1, no relationship was seen between plas-
ma concentrations of E3S and the pharmacokinetics of dar-
unavirorritonavir.Inthecurrentstudy,itispossiblethatun-
identiﬁed diﬀerences in baseline physiology between the po-
pulations undergoing sparse (n = 376) or intensive (n = 37)
pharmacokinetic sampling may also account for the fact that
nosex-baseddiﬀerencewasseenintheformerpopulation,in
contrastto thesmalldiﬀerencesseen in the latterpopulation.
Although the sample sizes were too small to draw any deﬁni-
tive conclusions for the etravirine intensive pharmacokinetic6 AIDS Research and Treatment
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Figure 1: Change in log10 viral load from baseline to Week 48 (nonvirologic failure censored) and virologic response by quartile ranges of
(a) darunavir AUC12h and C0h (sparse pharmacokinetic sampling; n = 376) and (b) etravirine AUC12h and C0h (sparse pharmacokinetic
sampling; n = 190). In Figures 1(a) and 1(b), the numbers within the boxplots represent the median values, the boxes represent the 25th
and 75th percentiles, and the whiskers represent the highest and lowest value within 1.5 interquartile range. AUC12h: area under the plasma
concentration–time curve over 12 hours; C0h: trough concentration; DRV: darunavir; non-VF: nonvirologic failure censored population;
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Table 4: Pharmacokinetics of darunavir, ritonavir, and etravirine (intense pharmacokinetic sampling).
Week 4 Week 24 Week 48
Mean ± SD AUC12h,n g ·h/mL n C0h,
ng/mL n AUC12h,
ng·h/mL n C0h,
ng/mL n AUC12h,
ng·h/mL n C0h,
ng/mL n
Darunavir
Overall 62,360 ±25,020 32 3559 ±
2385 26 62,230 ±
27,420 22 5042 ±
2080 20 56,320 ±
22,440 21 3388 ±
2078 21
Men
Overall 55,570 ±21,220 10 3863 ±
2402 8 51,510 ±
30,260 8 4765 ±
2240 6 52,040 ±
25,010 9 3406 ±
2134 9
Black 59,410 ± 26,060 6 4445 ±
3006 4 57,690 ±
36,900 5 5175 ±
2771 4 61,300 ±
28,130 4 3836 ±
2268 5
Hispanic 48,110 ± 14,160 3 3280 ±
1875 4 41,210 ±
15,070 3 3945 ±134 2 35,630 ±
11,440 4 1973 ±
1444 3
White 54, 910 1 — — — — — — 80, 630 1 5550 1
Women
Overall 65,440 ± 26,450 22 3424 ±
2434 18 68,360 ±
24,710 14 5160 ±
2085 14 59,540 ±
20,850 12 3375 ±
2131 12
Black 66,290 ± 29,930 16 3050 ±
2540 14 63,500 ±
22,080 11 5723 ±
1876 10 61,950 ±
23,570 9 3418 ±
2127 8
Hispanic 61,980 ±17,070 5 4877 ±
1968 3 86,170 ±
30,410 3 3753 ±
2139 4 52,290 ±
7973 3 3290 ±
2465 4
White 69,090 1 4310 1 — — — — — — — —
Ritonavir
Overall 5722 ± 3788 32 235 ± 223 26 6473 ±
4561 22 402 ± 326 20 5340 ±
2788 21 281 ± 187 21
Men
Overall 4399 ± 1876 10 276 ± 227 8 5047 ±
3409 8 296 ± 158 6 5611 ±
3480 9 318 ± 198 9
Black 5060 ± 1676 6 342 ± 260 4 6216 ±
3917 5 343 ± 143 4 7633 ±
3297 4 358 ± 171 5
Hispanic 3625 ± 2290 3 210 ± 204 4 3099 ±
941 3 201 ± 192 2 2833 ±
1620 4 180 ± 202 3
White 2755 1 — — — — — — 8639 1 537 1
Women
Overall 6324 ±4297 22 217 ± 225 18 7287 ±
5038 14 448 ± 371 14 5136 ±
2286 12 252 ±182 12
Black 5951 ± 4701 16 146 ± 149 14 7091 ±
5577 11 471 ±436 10 4773 ±
2354 9 209 ±136 8
Hispanic 6825 ±3191 5 457 ±354 3 8007 ±
2919 3 390 ± 144 4 6226 ±
2048 3 339 ±251 4
White 9782 1 491 1 — — — — — — — —
Etravirine
Overall 6980 ±4205 16 455 ± 238 14 5495 ±
3232 10 460 ±319 13 5520 ±
2756 9 375 ±215 12
Men
Overall 6636 ± 5720 8 409 ±305 6 4020 ±
1673 4 410 ±351 6 5694 ±
3729 5 382 ±278 6
Black 5919 ± 5840 4 563 ±392 3 2805 ±
888 2 265 ±209 2 2027 1 312 ±338 2
Hispanic 4165 ± 583 3 255 ± 88 3 5235 ±
1306 2 276 ±14 3 4819 ±383 3 273 ±73 3
White 16,910 1 — — — — 1100 1 11, 990 1 846 18 AIDS Research and Treatment
Table 4: Continued.
Week 4 Week 24 Week 48
Mean ± SD AUC12h,n g ·h/mL n C0h,
ng/mL n AUC12h,
ng·h/mL n C0h,
ng/mL n AUC12h,
ng·h/mL n C0h,
ng/mL n
Women
Overall 7323 ±2212 8 490 ± 188 8 6479 ±
3771 6 503 ±311 7 5304 ±
1265 4 369 ±156 6
Black 7381 ± 2383 7 465 ± 187 7 5902 ±
3910 5 456 ±313 6 5304 ±
1265 4 392 ± 162 5
Hispanic 6918 1 670 1 9362 1 783 1 — — 253 1
SD: standard deviation; AUC12h: area under the plasma concentration–time curve over 12 hours; C0h: trough concentration.
data by sex or race, results did seem consistent with the pop-
ulation pharmacokinetic results of this and other trials [7].
Intensive pharmacokinetic sampling showed notime-de-
pendent relationship for darunavir, ritonavir, or etravirine.
As observed in other studies of darunavir/ritonavir in treat-
ment-na¨ ıve and treatment-experienced patients [4, 14, 23],
no relevant relationships between darunavir pharmacoki-
netic parameters and the safety or eﬃcacy of darunavir/rito-
navir-based therapy were observed at Week 48 in the overall
population, by sex or by race. Week 48 was chosen for these
comparisons because we wanted to investigate the correl-
ationbetweensteady-statedrugexposureandresponseorVL
over the course of the study. Although no signiﬁcant sex-
based diﬀerence in virologic response rates was observed in
the GRACE study, black patients did have lower response
rates than white or Hispanic patients [8, 12]. Based on the
results of this study, however, this lower response rate is not
due to diﬀerences in pharmacokinetic proﬁles between racial
groups. Even though there was no signiﬁcant relationship
seen between darunavir pharmacokinetic parameters and
safety, it is possible that the slightly higher ritonavir exposure
in women may contribute to the small sex-based diﬀerences
in adverse events reported in the GRACE study; women re-
ported slightly higher rates of nausea and vomiting, whereas
men had higher rates of diarrhea [8].
A relationship between etravirine pharmacokinetic para-
meters and eﬃcacy was observed in this study. Patients
with etravirine AUC12h or C0h in the lowest quartile
(≤2712ng·h/mL or ≤160ng/mL, resp.) had the smallest
change in log10 VL from baseline to Week 48 and the lowest
response rates, compared with the other pharmacokinetic
quartiles.Theresponseratesofpatientsinthelowestquartile
of etravirine AUC12h were similar in the GRACE and DUET
trials (56.7% and 59.0%, resp.; nonvirologic-censored popu-
lations; data on ﬁle). GRACE was a single-armed study, so it
isdiﬃculttodeterminewhetherhavinglowpharmacokinetic
etravirineexposureitselforafactorcontributingtolowphar-
macokinetic etravirine exposure, such as nonadherence, is
contributing to the lower response rates in this group.
Norelevantrelationshipbetweenetravirinepharmacokinetic
parameters and the safety of etravirine was seen in this study.
PharmacokineticresultsfromGRACEdemonstratedthat
darunavir and etravirine exposures are not substantially af-
fected by sex and race, and that the darunavir C0h was above
the protein-binding corrected median eﬀective concentra-
tion (EC50) value for PI-resistant virus for all patients. These
results suggest that darunavir/ritonavir and etravirine ther-
apy are eﬀective in treatment-experienced men and women
and across races. Furthermore, no relevant relationship was
seen between darunavir pharmacokinetic parameters and a
range of extrinsic and intrinsic covariates, or the eﬃcacy
or safety of darunavir/ritonavir-based therapy. The response
rate obtained by those patients with the lowest etravirine
exposures in this study was substantially higher than the
responserateofpatientsinDUETwhoreceivednoetravirine
[24], suggesting that etravirine use may still be beneﬁcial to
treatment-experienced patients with lower etravirine expo-
sure. It should be noted that this study was conducted using
darunavir/ritonavir 600/100mg twice daily, which was the
approveddosefortreatment-experiencedpatientsatthetime
of the study. Since then, darunavir/ritonavir 800/100mg
once daily has been approved for treatment-experienced
patients with no darunavir resistance-associated mutations,
based upon results from the ODIN trial [6, 25]. Further
pharmacokinetic analyses will therefore be needed for this
newly approved dose.
5. Conclusion
These ﬁndings support the results from the overall GRACE
trial,whichshowedthatdarunavir/ritonavir-basedtherapyis
generally safe and eﬀective and that etravirine use is assoc-
iated with improved outcomes [8, 13], and suggest that dar-
unavir/ritonavir and etravirine may be administered without
dose adjustment in both sexes and across races.
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